Brief: Cardiol - Receives Clearance From FDA, Regulatory Agencies In Brazil, Mexico For Protocol Amendments To Expedite Patient Enrollment In Lancer Trial
01/03/2022 12:45
March 1 (Reuters) - Cardiol Therapeutics Inc CRDL.TO :
* CARDIOL - RECEIVES CLEARANCE FROM FDA, REGULATORY AGENCIES
IN
BRAZIL, MEXICO FOR PROTOCOL AMENDMENTS TO EXPEDITE PATIENT
ENROLLMENT IN LANCER TRIAL
* CARDIOL - LANCER TRIAL EXPANDED TO INCLUDE UP TO 20
ADDITIONAL
CLINICAL RESEARCH CENTERS
* CARDIOL - EXPECTS THE LANCER TRIAL TO ACHIEVE COMPLETE
FULL
PATIENT ENROLLMENT DURING THE SECOND HALF OF 2022
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM